Syndeio Biosciences
Michael G. McCully is an accomplished entrepreneur and executive with extensive experience in biotechnology and pharmaceutical industries. As Co-Founder, President, and Chief Operating Officer of Syndeio Biosciences since May 2025, McCully leads efforts in developing precision neurotherapeutics for central nervous system diseases. Previously, as Co-Founder, President, and Chief Executive Officer at Gate Neurosciences from December 2018 to May 2025, McCully played a pivotal role in raising over $90 million and merging with Boost Neurosciences. Other notable roles include President and CEO at Anagin Inc., Managing Director at Terranova Bioventures and RedLeaf Bioventures, and Chief Business Officer at Charleston Laboratories. McCully holds a Master's degree in Biotechnology and Business from Northwestern University and a Bachelor's degree in Plant Molecular Biology from Purdue University.
This person is not in any teams
This person is not in any offices
Syndeio Biosciences
Syndeio Biosciences (from the Ancient Greek word “to connect”) is a clinical-stage biotechnology company developing therapies to restore and enhance synaptic health in CNS disorders. The company’s proprietary Boost™ Synapse Pharmacology Platform combines electrophysiology, behavior, and human neuronal network assays to predict clinical outcomes with unprecedented accuracy. Syndeio’s clinical pipeline includes lead asset, zelquistinel, currently in Phase 2 development for major depressive disorder and will soon be entering an industry-first biomarker study in Alzheimer’s disease, and apimostinel, currently in an investigator-led phase 2 study for acute depression. The company is headquartered in Indianapolis, IN with research laboratories in Menlo Park, CA & Evanston, IL focused on advancing the Boost™ Synapse Pharmacology Platform.